Skip to content

Per-oral Endoscopic Myotomy (POEM) in Patients with Postfundplication Dysphagia

A Prospective Pilot Trial of Per-oral Endoscopic Myotomy (POEM) in Patients with Postfundplication Dysphagia (VADYSMA Trial)

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06872255
Acronym
VADYSMA
Enrollment
30
Registered
2025-03-12
Start date
2025-04-01
Completion date
2027-06-01
Last updated
2025-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dysphagia, Dysphagia, Esophageal, Healthy

Brief summary

Laparoscopic fundoplication represents the standard antireflux procedure, when conservative measures fail. However, any type of fundoplication may be accompanied by adverse events. Postfundoplication dysphagia (PFD) may hamper results of anti-reflux surgery. Endoscopic pneumatic dilation has been considered as the first line treatment option for persistent PFD. However, studies have not confirmed its effectiveness in this indication. Peroral endoscopic myotomy (POEM) became a standard treatment for the management of esophageal achalasia and moreover has also been assessed in a small cohort of patients with refractory PFD and some patients achieved significant treatment success. We plan to perform a prospective international cohort multicenter study assessing the efficacy of POEM in patients with persistent and severe PFD.

Interventions

All procedures will be performed by an experienced endoscopist, with a sufficient experience in third space endoscopy (at least 100 POEMs) under general anesthesia (internal preoperative examination is necessary) with a high-definition endoscope, fitted with a plastic distal attachment. Before the procedure, the patients will be administered intravenous antibiotics. Exclusively CO2 will be used for insufflation. POEM will be performed in a similar way as in patients with achalasia - the procedure consists of 4 steps: (1) mucosal incision and tunnel entry, (2) submucosal tunneling, (3) myotomy, and (4) closure of the mucosal entry with endoscopic clips or other closure devices. Perioperative protocol might differ according the usual way of performing POEM in a given center.

Sponsors

University Hospital Trnava
CollaboratorNETWORK
St. Anne's University Hospital Brno, Czech Republic
CollaboratorOTHER
Institute for Clinical and Experimental Medicine
Lead SponsorOTHER_GOV

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Patients with refractory (\> 6 months) and severe dysphagia after fundoplication procedure defined as an Eckardt score ≥3 and Mellow - Pinkas score ≥2 at baseline, with proven obstruction of gastroesofageal junction (EGJOO)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Patients after laparoscopic fundoplication procedure by Nissen (total, 360°), Dor (anterior, 180°) or Toupet (posterior, 270°) for gastroesophageal reflux disease no later than 10 years before enrolment. 2. Refractory (\> 6 months) and severe dysphagia after fundoplication procedure defined as an Eckardt score ≥3 and Mellow - Pinkas score ≥2 at baseline. 3. X-ray (contrasted radiographic examination of the esophagus) characterized by both: a.) tapered narrowing of the distal esophagus and GEJ; b.) partial/total stagnation of the contrast solution above the GEJ 4. Endoluminal planimetry: EGJ-DI \< 3 mm2/mmHg (with 40ml) 5. Age above 18 years 6. Signed informed consent form

Exclusion criteria

1. No previous attempt with at least one prokinetic drug 2. Previous esophageal myotomy (open, laparoscopic or endoscopic) 3. Primary esophageal motility disorder (achalasia etc.) 4. Active erosive esophagitis 5. Active peptic ulcer disease 6. Esophageal stricture (peptic, malignant, other) 7. Partial or complete supradiaphragmatic migration of the wrap and/or stomach (Hinder Type III - IV), Large hiatal hernia more than 5 cm 8. Known eosinophilic esophagitis 9. Severe coagulopathy 10. Esophageal or gastric varices 11. Advanced liver cirrhosis (Child B or Child C) 12. Pregnancy or puerperium 13. Malignant or pre-malignant esophageal diseases (dysplasia): patients with a history of such disease after its cure are eligible for enrolment 14. Any other condition, which in the opinion of the investigator would interfere with study requirements 15. Known gastroparesis

Design outcomes

Primary

MeasureTime frameDescription
Efficacy and safety of POEM in patients with postfundoplication dysfagia6 monthsThe primary outcome will be proportion of patients with treatment success defined as Eckardt score ≤ 2 and its decrease by at least 1 point after POEM at 6 months

Secondary

MeasureTime frameDescription
Mellow - Pinkas scoreAt baseline and after 3, 6 and 12 monthsThe Mellow - Pinkas score is used to assess dysphagia grade before and after the interventions. Total score ranges from 0 to 3 (0 = able to eat normal diet, 1 = able to swallow some solid foods, 2 = able to swallow only semi solid foods, 3 = able to swallow liquids only)
PAGI-QOL score (Patient Assessment of Upper Gastrointestinal Disorders-Quality of Life)At baseline and after 3, 6 and 12 monthsThe PAGI-QoL questionnaire contains of 30 items with five subscales: (1) daily activities; (2) clothing; (3) diet/food habits; (4) relationship; and (5) psychological well-being and distress. Each item is scored on a 6-point Likert scale, with response options ranging from 0 (none) to 5 (severe problem all of the time). Subscale scores are calculated by averaging the item responses. A total score is calculated by averaging subscale scores. Higher score means impairment in quality of life.
GERD-RHQL score (Gastroesophageal Reflux Disease Health-related Quality of Life)At baseline and after 3, 6 and 12 monthsThe GERD-HRQL questionnaire was developed and validated to measure changes of typical GERD symptoms such as heartburn and regurgitation in response to surgical or medical treatment. Higher (greater) possible score means worst symptoms - ranging from 0 to 75.
Integrated Relaxation Pressure (IRP)At baseline and after 6 monthsHigh resolution manometry - Median IRP recorded from 10 supine swallows, measured in mmHg. A value \>15 mmHg indicates EGJ outflow obstruction.
Eckardt scoreAt baseline and after 3, 6 and 12 monthsThe Eckardt score is the grading system used for the evaluation of severity of symptoms in patients with esophageal achalasia. Four symptoms are assessed (dysphagia, regurgitation, chest pain and weight loss) and their severity ranges from 0 (no symptom) to 3 (with every meal). Total score is their sum and ranges from 0 to 12
EsophagogramAt baseline and after 6 monthsEsophagogram provides valuable information of the fundoplication, better appreciate a paraesophageal hernia and information on esophageal emptying. Patients will be advised overnight fasting prior to timed barium esophagogram. A contrast agent (e.g. barium, usually 100 to 250 mL) is ingested orally within 15-20 seconds. Left posterior oblique X-ray will be taken 2 and 5 minutes after contrast agent ingestion. Maximum esophageal width and column hights will be recorded at 2 and 5 minutes.
GERDAt baseline and after 3, 6 and 12 monthsPresence of reflux esophagitis based on endoscopy findings.
Esophageal 24h-Hour pH metryAt 3 months after procedureAn esophageal pH test measures how often stomach acid enters to the esophagus. It also measures how long the acid stays there. The test involves placing a catheter into the esophagus. The catheter or device will measure an acid level (known as pH level) for 24 hours. Post-POEM Esophageal acid exposure (DeMeester score, proportion of time with pH below 4)After
PPI/H2 antagonistsAt baseline and after 3, 6 and 12 monthsPPI's and/or H2 antagonists use before and after procedure (POEM).
Endoluminal planimetry (Endoflip)At baseline and after 6 monthsPyloric distensibility measured by impedance planimetry (EndoFLIP device)

Countries

Czechia, Slovakia

Contacts

Primary ContactJan Martínek, prof., MD
jan.martinek@fnusa.cz+420 723 708 839
Backup ContactMartin Vašátko, MD
martin.vasatko@fnusa.cz+420 739 476 451

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026